Media headlines about NanoString Technologies (NASDAQ:NSTG) have trended somewhat positive on Saturday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. NanoString Technologies earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.208962293489 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Several brokerages have issued reports on NSTG. Zacks Investment Research raised NanoString Technologies from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Wednesday, July 5th. Cowen and Company reaffirmed a “buy” rating on shares of NanoString Technologies in a research note on Friday, July 14th. ValuEngine raised NanoString Technologies from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub lowered NanoString Technologies from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. NanoString Technologies has an average rating of “Hold” and a consensus target price of $19.00.

Shares of NanoString Technologies (NASDAQ NSTG) traded up 0.06% during mid-day trading on Friday, reaching $16.16. The company’s stock had a trading volume of 43,689 shares. The company’s 50-day moving average price is $15.03 and its 200-day moving average price is $16.94. The stock’s market capitalization is $407.30 million. NanoString Technologies has a 12-month low of $13.17 and a 12-month high of $23.45.

NanoString Technologies (NASDAQ:NSTG) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.17. NanoString Technologies had a negative return on equity of 329.59% and a negative net margin of 44.28%. The business had revenue of $34.59 million for the quarter, compared to the consensus estimate of $29.87 million. On average, equities research analysts forecast that NanoString Technologies will post ($2.12) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at

NanoString Technologies Company Profile

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Insider Buying and Selling by Quarter for NanoString Technologies (NASDAQ:NSTG)

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.